Molecular Radiotherapy and Therapeutic Innovation

This team belongs to the UMR 1030 - Molecular radiotherapy and therapeutic innovations

Our team is composed of 2 groups:

• The Cell death, Immunity and Therapeutic Innovation group led by Dr. Jean-Luc PERFETTINI
• The Radiotherapy, ImmunoRadAI group led by Pr. Eric DEUTSCH

The REMISSION program was granted by the 6^th call for projects of the Hospital-University Research (RHU) endeavor of the France 2030 government investment plan. It proposes to use fresh tissues (blood and tumor) as a source of biomarkers to adapt new immunotherapy strategies to the biology of patients and their cancer. This program aligns with Gustave Roussy's objectives to personalize treatments for cancer patients.

Immunothérapie : les vaccins thérapeutiques

Lors de la dernière décennie, la révolution entraînée par l’immunothérapie en cancérologie a permis des avancées majeures au bénéfice du patient. Les chercheurs ne visent plus uniquement à s’attaquer directement aux cellules cancéreuses, comme le font la chimiothérapie ou la radiothérapie, mais à renforcer le système immunitaire du malade pour qu’il les élimine lui-même.  

Chromatin function in DNA repair

Contacts

Beatrice Rondinelli
ATIP/Avenir team “Chromatin function in DNA repair"
Genome Integrity & Cancers
UMR9019 – CNRS Paris-Saclay
GUSTAVE ROUSSY  - PR2, Room 401
114, rue Edouard Vaillant
94805 - Villejuif Cedex
FRANCE
Email : beatrice.rondinelli@gustaveroussy.fr

Chromatin function in DNA repair

Chromatin function in DNA repair

This group belongs to the UMR 9019 Genome Integrity and Cancers.

CARE1: A European Study on First-Line Treatment of Metastatic Kidney Cancer

LySAIRI: towards an innovative radiotherapy that facilitates immune sparing to improve overall clinical efficacy

Laurie Menger

Biography